Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade Therapy.

Cancer research - 15 Oct 2025

Lin De-Chen, Shen Keyue

Abstract excerpt

Loss-of-function mutations in STK11 (also known as LKB1) define a molecular subtype of non-small cell lung cancer that is resistant to immune checkpoint blockade therapy, partially owing to impaired T-cell infiltration and suppressed antigen presentation. Emerging evidence implicates epigenetic deregulation as a key driver of immune evasion in STK11-mutant tumors. In this issue of Cancer Research, Ahronian and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to STK11 gene

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Serine-Threonine Kinases

Source

Identifiers

PMID: 41088878
DOI: 10.1158/0008-5472.CAN-25-4003

Genes

STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade Therapy.PMID 41088878Read ↗

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Semantic proximity Read ↗

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC.Semantic proximity Read ↗

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.Semantic proximity Read ↗

Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1 , SMARCA4 , and PTEN mutationsSemantic proximity Read ↗

Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.Semantic proximity Read ↗

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Semantic proximity Read ↗

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.Semantic proximity Read ↗

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.Semantic proximity Read ↗

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.Semantic proximity Read ↗

A transcriptional signature of LKB1 functional loss defines a large, therapeutically addressable patient population across human cancersSemantic proximity Read ↗

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.